{"id":"W4283326517","doi":"10.1097/01.hs9.0000843644.02496.66","title":"S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY-BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Oncology; Multiple myeloma; Adverse effect; Phases of clinical research; Refractory (planetary science); Clinical trial; Bortezomib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002688325,0.0002578721,0.0004406534,0.0001415067,0.0003125897,0.00001657753,0.0001575207,0.00007029578,0.0000999096],"category_scores_gemma":[0.0000703742,0.0001638535,0.0001417101,0.0005677259,0.0001160638,0.00005841336,0.00002350733,0.0002025973,0.000001251161],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005956608,"about_ca_system_score_gemma":0.0003923757,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000464996,"about_ca_topic_score_gemma":0.0001423935,"domain_scores_codex":[0.9981762,0.0001028074,0.000437453,0.0004269386,0.0004878434,0.0003687232],"domain_scores_gemma":[0.9984469,0.0004522394,0.0002069105,0.0006553283,0.0001571002,0.00008149917],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4144123,0.2726951,0.02081575,0.0008676185,0.003393827,0.0003917471,0.005264855,0.007186006,0.03948285,0.0007357068,0.005013553,0.2297406],"study_design_scores_gemma":[0.6621848,0.03387045,0.01181032,0.0001506592,0.0003189195,0.00004104717,0.003596973,0.1698995,0.02093859,0.00002135923,0.09669039,0.00047704],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9594774,0.004302337,0.01629328,0.00137496,0.0001463291,0.01257668,0.002123184,0.0001587624,0.003547057],"genre_scores_gemma":[0.9863131,0.00005120038,0.007209936,0.00006382853,0.00001951776,0.002218717,0.002371971,0.00004122732,0.0017105],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2477724,"threshold_uncertainty_score":0.6681753,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03588206454185491,"score_gpt":0.3080620892896637,"score_spread":0.2721800247478088,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}